No Data
No Data
Neurizon Therapeutics Moves to Lift FDA Suspension on NUZ-001 Drug Candidate With Two Studies; Shares Fall 5%
Investing in Neurizon Therapeutics (ASX:NUZ) Five Years Ago Would Have Delivered You a 54% Gain
Neurizon Therapeutics Ltd: Appendix 4D - Half-year Financial Report - 31 December 2024
Neurizon Gets US Patent for Cancer Drug Candidate; Shares Up 16%
Neurizon Therapeutics Says FDA Places Its Investigational New Drug Application on Hold; Shares Hit New 52-Week Low
Neurizon's ALS Drug Candidate Receives Orphan Medicinal Product Designation in Europe; Shares Down 3%